We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Isis Finds a Secure Port in the Storm

01 Apr 1995

Executive Summary

Isis Pharmaceuticals has pursued antisense with a single-mindedness sharply contrasting to its two major California competitors, Gilead and Genta, who have each adopted theoretically nearer-term, strategies. Of the three, Isis is the alliance king, as its recent deal with Boehringer Ingelheim makes clear.